Equity Overview
Price & Market Data
Price: $5.56
Daily Change: -$0.13 / 2.34%
Daily Range: $5.41 - $5.69
Market Cap: $526,587,968
Daily Volume: 312,022
Performance Metrics
1 Week: -1.25%
1 Month: -14.13%
3 Months: 2.98%
6 Months: 54.47%
1 Year: 380.9%
YTD: 5.54%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.